Menu
en
fr
nl
About Us
Bone Therapeutics in brief
Mission
Management
Board of Directors
Scientific Advisory Board
Team
Technology
Unique technology platform
Intellectual property
Products
Pipeline
ALLOB
JTA-004
Indications
Clinical studies
General information
Ongoing studies
Investigator interviews
Participation
Partnering
Our Partners
Licensing Opportunities
Investors
Share Price
Shareholder Information
Financial Calendar
Financial Information
Regulated Information
Governance
Shareholders Meeting
Presentations
Events
IR Contact
Careers
Job Opportunities
Spontaneous Applications
Testimonials
News & Events
Press Releases
Media Coverage
News
Upcoming Events
Newsletter Subscription
10 Years
Contact
Contact
if you are a robot type something
Home
News & Events
Press Releases
Press releases
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
July
7/27/21 - Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017
7/19/21 - Bone Therapeutics provides update on the progress of clinical studies
7/12/21 - Bone Therapeutics appoints Anne Leselbaum, MD as Chief Medical Officer
7/5/21 - Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 5 August 2021
7/1/21 - Bone Therapeutics secures up to €16M loan financing from the EIB to accelerate clinical and commercial development of innovative orthopedic treatments
June
6/30/21 - Bone Therapeutics publishes results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy
6/10/21 - Bone Therapeutics announces Annual General Meeting results
May
5/26/21 - Bone Therapeutics Provides First Quarter 2021 Business Update
5/20/21 - Bone Therapeutics to participate in upcoming conferences
5/7/21 - Bone Therapeutics to host Annual General Meeting on 9 June 2021
April
4/29/21 - Bone Therapeutics announces 2020 full year results
March
3/30/21 - Bone Therapeutics appoints industry cell therapy expert, Anthony Ting, PhD as Chief Scientific Officer
3/17/21 - Bone Therapeutics to present in M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conference
February
2/9/21 - Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 26 February 2021
January
1/20/21 - Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook
1/14/21 - Bone Therapeutics and Rigenerand sign partnership for cell therapy process development
1/12/21 - Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
1/8/21 - Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021
December
12/24/20 - Transparency notification received from CPH Banque
12/24/20 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2020)
12/22/20 - Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
12/16/20 - Bone Therapeutics announces closing of private placement
12/11/20 - Bone Therapeutics announces pricing of private placement
November
11/16/20 - Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
11/10/20 - Bone Therapeutics, Cerhum, 3D-Side, mSKIL and IREC awarded €3M in BioWin supported funding to develop personalized, tissue engineered bone implants
October
10/30/20 - Bone Therapeutics Provides Third Quarter 2020 Business Update
10/29/20 - Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
10/23/20 - Transparency notification received from S.R.I.W. SA and Sofipôle SA
10/23/20 - Bone Therapeutics: Information on the total number of voting rights and shares (October 2020)
10/20/20 - Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
10/14/20 - Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
10/12/20 - Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa
10/5/20 - Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
September
9/9/20 - Information on the total number of voting rights and shares
August
8/26/20 - Bone Therapeutics reports half year 2020 results
8/20/20 - Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region
8/13/20 - Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study
June
6/11/20 - Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020
May
5/29/20 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
5/29/20 - Bone Therapeutics: Information on the total number of voting rights and shares (May 2020)
5/18/20 - Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
5/11/20 - Bone Therapeutics to host Annual Ordinary General Meeting on 10 June 2020
5/7/20 - Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15 million committed, providing runway into Q2 2021
5/6/20 - Bone Therapeutics Provides First Quarter 2020 Business Update
April
4/29/20 - Bone Therapeutics secures EUR 11.0 million financing
4/3/20 - Bone Therapeutics: Information on the total number of voting rights and shares (March 2020)
March
3/26/20 - Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer
3/23/20 - Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
3/11/20 - Bone Therapeutics announces 2019 full year results
February
2/28/20 - Bone Therapeutics: Information on the total number of voting rights and shares (February 2020)
2/11/20 - Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the ORS
January
1/31/20 - Bone Therapeutics: Information on the total number of voting rights and shares (January 2020)
1/22/20 - Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
1/9/20 - Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference
December
12/30/19 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2019)
12/20/19 - Bone Therapeutics advances JTA-004 into pivotal Phase III study
12/19/19 - Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development
12/9/19 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
November
11/29/19 - Bone Therapeutics: Information on the total number of voting rights and shares (November 2019)
11/25/19 - Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available
11/6/19 - Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update
October
10/22/19 - Bone Therapeutics: The preliminary documents for the Extraordinary General Shareholder Meeting on 22 November 2019 have been made available
10/3/19 - Bone Therapeutics: Information on the total number of voting rights and shares (September 2019)
September
9/27/19 - Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics
9/9/19 - Bone Therapeutics: Information on the total number of voting rights and shares (August 2019)
August
8/30/19 - Bone Therapeutics reports half year 2019 results
8/28/19 - Bone Therapeutics to report half year 2019 results on 30 August 2019
July
7/30/19 - Bone Therapeutics: Information on the total number of voting rights and shares (July 2019)
7/11/19 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
7/4/19 - Bone Therapeutics: Transparency notification received from Mr. J. Reymann
7/2/19 - Bone Therapeutics: Information on the total number of voting rights and shares
June
6/27/19 - Bone Therapeutics successfully raises EUR 8.5 million
6/27/19 - Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds
6/21/19 - Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)
6/13/19 - Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
6/13/19 - Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
6/12/19 - Bone Therapeutics announces results of Annual General Meeting
May
5/31/19 - Bone Therapeutics to participate in upcoming conferences
5/29/19 - Bone Therapeutics: Information on the total number of voting rights and shares (May 2019)
5/24/19 - Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019
5/24/19 - The preliminary documents for the Extraordinary General Shareholder Meeting on 12 June 2019 have been made available
5/10/19 - The preliminary documents for the Annual Ordinary General Shareholder Meeting on 12 June 2019 have been made available
5/7/19 - Bone Therapeutics Provides First Quarter 2019 Business Update
April
4/29/19 - Bone Therapeutics: Information on the total number of voting rights and shares (April 2019)
4/25/19 - Bone Therapeutics announces publication of Annual Report 2018 and Extraordinary General Meeting on 23 May 2019
4/23/19 - The preliminary documents for the Extraordinary General Shareholder Meeting on 23 May 2019 have been made available
March
3/28/19 - Bone Therapeutics: Information on the total number of voting rights and shares (March 2019)
3/18/19 - Bone Therapeutics to present at Herbert Fleisch / IFMRS Workshop
3/12/19 - Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer
3/5/19 - Bone Therapeutics: Information on the total number of voting rights and shares (February 2019)
3/1/19 - Bone Therapeutics announces 2018 full year results
February
2/25/19 - Bone Therapeutics Notice of Full Year 2018 Results
2/5/19 - Bone Therapeutics to present at the Annual Meeting of the Orthopaedic Research Society (ORS)
January
1/30/19 - Bone Therapeutics: Information on the total number of voting rights and shares (January 2019)
1/30/19 - Bone Therapeutics holds successful event to highlight strength of cell and gene therapy in Wallonia
1/22/19 - Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
December
12/24/18 - Bone Therapeutics: Information on the total number of voting rights and shares (December 2018)
12/11/18 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
November
11/29/18 - Bone Therapeutics: Information on the total number of voting rights and shares (November 2018)
11/7/18 - Bone Therapeutics Business Update for Third Quarter 2018
11/6/18 - Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis
October
10/29/18 - Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer
10/25/18 - Bone Therapeutics: Information on the total number of voting rights and shares (October 2018)
10/17/18 - Single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis
September
9/27/18 - Bone Therapeutics: Information on the total number of voting rights and shares (2018-09)
9/24/18 - Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society
9/14/18 - Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study
9/3/18 - Bone Therapeutics: Information on the total number of voting rights and shares
August
8/30/18 - Bone Therapeutics Announces H1 Results for 2018
8/8/18 - Bone Therapeutics Notice of Half Year 2018 Results
July
7/20/18 - Bone Therapeutics: Information on the total number of voting rights and shares
June
6/21/18 - The preliminary documents for the Extraordinary General Shareholder Meeting on 9 July 2018 have been made available
6/14/18 - Bone Therapeutics announces results of Annual General Meeting
6/11/18 - Bone Therapeutics: Information on the total number of voting rights and shares
May
5/28/18 - Bone Therapeutics: Information on the total number of voting rights and shares
5/9/18 - The preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting on 13 June 2018 have been made available
5/4/18 - Bone Therapeutics Business Update for First Quarter 2018
5/4/18 - Bone Therapeutics: Information on the total number of voting rights and shares
April
4/26/18 - Bone Therapeutics Strengthens Board with the Appointment of Claudia D'Augusta as Non-Executive Director
4/25/18 - Bone Therapeutics Reports Full Year 2017 Results
4/4/18 - Bone Therapeutics: Transparency notification received from S.R.I.W. SA and Sofipôle SA
March
3/21/18 - Bone Therapeutics: Information on the total number of voting rights and shares
3/7/18 - Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement
3/7/18 - Bone Therapeutics Announces Private Placement of Convertible Bonds
February
2/20/18 - Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman
2/19/18 - Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
January
1/23/18 - Bone Therapeutics provides business outlook and announces its financial calendar for 2018
1/19/18 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2018
December
12/15/17 - Bone Therapeutics Provides Update on Equity Placement
12/14/17 - Bone Therapeutics Launches Equity Placement
12/11/17 - Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline
November
11/9/17 - Bone Therapeutics Business Update for Third Quarter 2017
October
10/24/17 - Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017
10/13/17 - The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available
September
9/22/17 - Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan
9/20/17 - Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
9/14/17 - Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study
9/4/17 - The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available
August
8/31/17 - Bone Therapeutics announces H1 results for 2017
8/31/17 - Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
8/24/17 - Bone Therapeutics Notice of Half Year 2017 Results
July
7/3/17 - Bone Therapeutics strengthens board of directors
June
6/26/17 - Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform
6/8/17 - Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB
May
5/29/17 - Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors
5/11/17 - Bone Therapeutics Business Update for First Quarter 2017
April
4/26/17 - Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available
4/25/17 - Bone Therapeutics announces the publication of its Annual Report 2016
March
3/16/17 - Bone Therapeutics Reports Full Year 2016 Results
3/10/17 - Bone Therapeutics to participate in upcoming key investor conferences
3/9/17 - Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study
3/6/17 - Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer
3/3/17 - Bone Therapeutics Notice of Full Year 2016 Results
January
1/20/17 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2017
1/17/17 - Bone Therapeutics Provides Business Update for Q4 2016
1/6/17 - Bone Therapeutics Granted EUR 2.3 Million in Non-Dilutive Funding by the Walloon Region
December
12/21/16 - Bone Therapeutics announces its financial calendar for 2017
November
11/8/16 - Bone Therapeutics Business Update for Third Quarter 2016
11/2/16 - Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016
October
10/11/16 - Enrico Bastianelli to stand down as CEO of Bone Therapeutics
10/11/16 - Transparency notification received from Theodorus II SA
10/5/16 - Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial
September
9/15/16 - Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction
August
8/30/16 - Bone Therapeutics announces H1 results for 2016
8/25/16 - Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016
June
6/8/16 - Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
6/3/16 - Bone Therapeutics celebrates ten years of innovation in bone cell therapy
May
5/19/16 - Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
5/17/16 - Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
5/10/16 - Bone Therapeutics Provides Business Update for the First Quarter of 2016
5/3/16 - Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study
April
4/26/16 - The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
4/14/16 - Bone Therapeutics announces the publication of its Annual Report 2015
March
3/29/16 - Bone Therapeutics Reports Full Year 2015 Results
3/29/16 - Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
3/16/16 - Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016
February
2/24/16 - Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
2/17/16 - Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
2/17/16 - Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
2/2/16 - Bone Therapeutics extends Kasios collaboration
January
1/20/16 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
1/18/16 - Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
1/13/16 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
1/5/16 - Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region
December
12/23/15 - Bone Therapeutics announces its financial calendar for 2016
12/15/15 - Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial
12/11/15 - ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference
November
11/30/15 - Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
11/18/15 - Bone Therapeutics Provides Business Update for the Third Quarter of 2015
11/12/15 - Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA
11/9/15 - Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer
October
10/22/15 - Transparency notification received from S.R.I.W. SA & Sofipôle SA
10/13/15 - Bone Therapeutics to participate in key investor conferences in Q4 2015
September
9/28/15 - Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
9/22/15 - Bone Therapeutics announces half-year results for 2015
9/21/15 - Bone Therapeutics Notice of Half Year Results 2015
9/7/15 - Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial
June
6/22/15 - Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis
May
5/15/15 - Bone Therapeutics Provides Business Update for the First Quarter 2015
April
4/28/15 - Bone Therapeutics Reports 2014 Financial and Operational Results
4/24/15 - Bone Therapeutics officially opens its new headquarters in Gosselies
4/13/15 - Bone Therapeutics Establishes US Subsidiary
March
3/23/15 - Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
3/2/15 - Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial
February
2/19/15 - Information on the total number of voting rights and shares
2/18/15 - Bone Therapeutics announces its financial calendar for 2015
2/17/15 - Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
2/16/15 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
2/11/15 - Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
2/4/15 - Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris
January
1/21/15 - Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
1/19/15 - Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
1/16/15 - Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
1/5/15 - Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product
December
12/4/14 - Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®
November
11/17/14 - Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures
October
Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany
September
Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)
July
Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products
June
Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product
January
Bone Therapeutics to present at Biotech Showcase in San Francisco on Tuesday 14 January, 2014 at 10.15am
December
Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant
November
Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures
October
Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial
September
Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer
June
Establishment of the Walloon Cell Therapy Platform: The platform aims to produce cell therapy medicines on a large scale
Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle
April
Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
Bone Therapeutics to Present at Upcoming Investor Conferences
March
Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products
February
Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
January
Bone Therapeutics Raises €7.7 Million in Series D Fundraising
October
Bone Therapeutics receives clearance for its pivotal phase III osteonecrosis trial with PREOB® in Europe and treats the first patients in the study
Bone Therapeutics reçoit l'approbation des autorités et traite les premiers patients dans son étude clinique de phase III en ostéonécrose avec son produit PREOB®
February
Bone Therapeutics lève 9,5M €
June
Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel
